Clinical recognition and management of patients exposed to biological warfare agents

Clinics in Laboratory Medicine

Volumn 21, Issue 3, 2001, Pages 435-473

  Franz, D R ^a   Jahrling, P B ^a   McClain, D J ^a   Hoover, D L ^a   Byrne, W R ^a   Pavlin, J A ^a   Christopher, G W ^a   Cieslak, T J ^a   Friedlander, A M ^a   Eitzen E M , Jr ^a  

^a 365 West Patrick Street ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BOTULINUM ANTISERUM; CHLORAMPHENICOL; CIDOFOVIR; CIPROFLOXACIN; DOXYCYCLINE; GENTAMICIN; PENICILLIN G; RIBAVIRIN; RICIN; STAPHYLOCOCCUS ENTEROTOXIN B; STREPTOMYCIN; TOXIN;

ANTHRAX; BACTERIUM; BIOLOGICAL WARFARE; BOTULISM; BRUCELLOSIS; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; ENVIRONMENTAL EXPOSURE; GOVERNMENT; HEALTH CARE POLICY; HUMAN; INCUBATION TIME; INFECTION; INFECTION CONTROL; INFECTION PREVENTION; PLAGUE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; Q FEVER; REVIEW; SMALLPOX; SYMPTOM; TULAREMIA; VIRUS INFECTION;

EID: 0034821997     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0272-2712(18)30018-0     Document Type: Review

References (206)

1. Pathology of inhalational anthrax in 42 cases from the Sverdlosk outbreak of 1979
2. Vaccine prophylaxis of Q fever
3. Evaluation of castor bean toxicosis in dogs: 98 Cases
4. Human brucellosis: A classical infectious disease with persistent diagnostic challenges
5. Virological evidence for the success of the smallpox eradication programme
6. Brucellar spondylitis
7. Post-infection fatigue syndrome following Q fever
8. Prophylactic treatment of smallpox contacts with N-methylisatin-thiosemicarbasone (compound 33T57, Marboran)
9. Recurrent reaction at site of Q fever vaccination in a sensitized person
10. Q fever vaccine
11. Inhalation anthrax
12. Anthrax
13. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge
14. The frequency of VEE virus in the pharyngeal material of clinical cases of encephalitis
15. Rural epidemic encephalitis in Venezuela caused by a group A arbovirus (VEE)
16. Chronic Q fever
17. Immunization against tularemia
18. Hantaviruses and hantivirus pulmonary syndrome
19. Yersinia species including plague
20. Development of vaccines for prevention of botulism
21. Antibiotic treatment of experimental pneumonic plague in mice
22. Complex specific immunoglobulin M antibody patterns in humans infected with Alphaviruses
23. Arbovirus serogroups: Definition and geographic distribution
24. In-vivo activity of antivirals against exotic RNA viral infections
25. General medicine and infectious diseases
26. Plague immunization
27. Bioterrorism alleging use of anthrax and interim guidelines for management - United States, 1998
28. Ebola in Sudan
29. Fatal illness associated with a New-World Arenavirus - California, 1999-2000
30. Human monkeypox - Kasai oriental, Zaire
31. Management of patients with suspected viral hemorrhagic fever
32. Endocarditis caused by Brucella melitensis
33. Two non-fatal human infections with the virus of eastern encephalitis
34. Biological warfare research in the United States
35. New Arenavirus isolated in Brazil
36. Bioterrorism threats: Learning from inappropriate responses
37. Comparative trial of doxycycline plus streptomycin versus doxycycline plus rifampin for the therapy of human brucellosis
38. Complications associated with brucella melitensis infection: A study of 530 cases
39. Aerosol delivery of limpsome-encapsulated ciprofloxacin: Aerosol characterization and efficacy against Francisella tularensis infection in mice
40. Death in a pellet
41. Hematologic changes in brucellosis
42. Attenuating mutations in the E2 glycoprotein gene of Venezuelan equine encephalitis virus
43. Clinical and neuroradiographic manifestations of eastern equine encephalitis
44. The course of infection with Coxiella burnetii
45. The recovery of smallpox from patients and their environment in a smallpox hospital
46. Studies on the virus content of mouth washings in the acute phase of smallpox
47. An important outbreak of human Q fever in a Swiss alpine valley
48. Anthrax
49. Rift Valley fever
50. Importance of neutralizing antibodies in treatment of Argentine hemorrhagic fever with immune plasma
51. Antiviral treatment of Argentine hemorrhagic fever
52. Comments on the early history of human brucellosis
53. Tularemia
54. Tularemia
55. Identification of Bacillus anthracis by using monoclonal antibody to cell wall galactose-N-acetylglucosame polysaccharide
56. Equine encephalitis in Massachusetts
57. Q fever meningoencephalitis in a soldier returning from the Persian Gulf War
58. Brucella abortus infection acquired in microbiology laboratories
59. Human infection due to Ebola virus, subtype Cote d'Ivoire: Clinical and biologic presentation
60. Phase I study of the plant protein ricin
61. An outbreak of Venezuelan equine encephalitis in man in the Panama Canal Zone
62. Ricin toxin
63. Clinical recognition and management of patients exposed to biological warfare agents
64. The US biological warfare and biological defense programs
65. Efficacy of prophylactic and therapeutic administration of antitoxin for inhalation botulism
66. High-affinity binding of staphylococcal enterotoxins A and B to HLA-DR
67. Anthrax
68. Postexposure prophylaxis against experimental inhalation anthrax
69. Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses
70. Ebola hemorrhagic fever outbreaks in Gabon, 1994-1997
71. Bacterial toxins: A table of lethal amounts
72. Equine encephalomyelitis in a laboratory technician with recovery
73. The 1959 outbreak of eastern encephalitis in New Jersey
74. Seized poison set off few alarms
75. Articular involvement in human brucellosis
76. An evaluation of diagnostic methods for brucellosis
77. Molecular typing of brucella with cloned DNA probes
78. Protection against anthrax toxin by vaccination with a DNA plasmid encoding anthrax protective antigen
79. Airborne microorganisms
80. An outbreak of eastern equine encephalomyelitis in Jamaica, West Indies, Nov-Dec 1962. I: Description of human cases
81. Improved mucosal protection against Venezuelan equine encephalitis virus is induced by the molecularly defined, live- attenuated V3526 vaccine candidate
82. Eastern and Western encephalitis
83. Protection against experimental bubonic and pneumonic plague with a recombinant capsular F1-V antigen fusion protein vaccine
84. Smallpox
85. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates
86. Venezuelan equine encephalomyelitis
87. Cross immunity experiments in monkey between variola, alastrim and vaccinia
88. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug
89. Biochemical and biological characteristics of epitopes on the E1 glycoprotein of western equine encephalitis virus
90. Veterinary services in biological disasters
91. Genito-urinary complications of brucellosis
92. The potential of 5 nuclease PCR for detecting a single-base polymorphism in orthopoxviruses
93. Plague as a biological weapon
94. Evaluation of specificity of indirect enzyme-linked immunosorbent assay for diagnosis of human Q fever
95. The characterization of brucella strains isolated from marine mammals
96. Filoviruses and arenaviruses
97. Endemic Lassa fever in Liberia
98. Passive immunization of Ebola virus-infected cynomulgus monkeys with immunoglobulin from hyperimmune horses
99. Human monkeypox
100. Venezuelan equine encephalitis
101. Virus isolations from human cases of hemorrhagic fever in Bolivia
102. VB(Beta)-specific stimulation of human T cells by staphylococcal toxins
103. International catalogue of arboviruses including certain other viruses of vertebrates
104. A study on the morphological and cyto-immunological relationship between the inclusions of variola, cowpox, rabbitpox, vaccinia (variola origin) and vaccinia IHD and consideration of the term "Guarneri body"
105. Man is arrested in a 'case involving deadly poison
106. Rapid and sensitive immunomagnetic-electrochemi-luminescent detection of staphyloccocal enterotoxin B
107. Treatment of Bolivian hemorrhagic fever with intravenous ribavirin
108. Immune response to staphylococcal superantigens
109. Intradermal sensitivity testing in man with a purified vaccine for Q fever
110. Biological warfare defense 2
111. Developing national preparedness for smallpox: An update
112. Hemorrhagic fever with renal syndrome in Korea
113. Sequelae of Venezuelan equine encephalitis in humans: A four-year follow-up
114. Survival of variola virus in raw cotton
115. Progressive extension of the endemic area and changing incidence of Argentine hemorrhagic fever
116. Coxiella burnetii (Q fever) pneumonia
117. Truckin' pneumonia: An outbreak of Q fever in a truck repair plant
118. Vaccine prophylaxis of abbattoir-associated Q fever
119. An epidemiological study of Venezuelan equine encephalomyelitis in Costa Rica
120. Determination of the protective epitopes on the glycoproteins of Venezuelan equine encephalomyelitis virus by passive transfer of monoclonal antibodies
121. Lassa fever: Effective therapy with ribavirin
122. A prospective study of epidemiology and ecology of Lassa fever
123. Aerosol infection of man with Pasteurella tularesis
124. Chloramphenicol and terramycin in the treatment of pneumonic plague
125. Use of an attenuated strain of Venezuelan equine encephalomyelitis virus for immunization in man
126. Air sampling to recover variola virus in the environment of a smallpox hospital
127. The Sverdlosk anthrax outbreak of 1979
128. Contributions of the U.S. Army to botulinum toxin research
129. Pleuropulmonary tularemia
130. Virus content of smallpox scabs
131. Class II MHC molecules are specified receptors for staphylococcal enterotoxin A
132. Yellow fever: Epidemics and search in the last forty years and prospects for the future
133. Posttreatment follow-up of brucellosis by PCR assay
134. Safety and efficacy of a mutagen-attenuated Rift Valley fever vaccine in cattle
135. Brucellosis in Kuwait
136. The nature of human brucellosis in Kuwait: Study of 379 cases
137. Osteoarticular complications of brucellosis
138. Brucella
139. The price of fanaticism
140. An outbreak of Brucella melitensis infection by airborne transmission among laboratory workers
141. Smallpox: An attack scenario
142. Biological warfare defense
143. Brucellos and heart disease
144. Francisella tularensis (tularemia)
145. Filoviruses and management of viral hemorrhagic fever
146. Immunogenicity of an inactivated Rift Valley fever vaccine in humans: A 12-year experience
147. Expression of cereolysine AB genes in Bacillus anthracis vaccine strain insures protection against experimental hemolytic anthrax infection
148. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus
149. Rapid diagnosis of human brucellosis by peripheral-blood PCR assay
150. The toxicity, distribution, and excretion of ricin holotoxin in rats
151. Assessment of an isothiazole thiosemicarbazone in the prophylaxis of contacts of variola major
152. Treatment of Q fever
153. State-of-the-art clinical lecture: Q fever
154. Castor bean toxicity re-examined: A new perspective
155. The efficacy of ciprofloxacin and doxycycline against experimental tularemia
156. Venezuelan hemorrhagic fever
157. Q fever in an urban area
158. California anthrax threats spawn costly wave of fear
159. Virus excretion in smallpox
160. Antibiotic prophylaxis and therapy of airborne tularemia
161. Treatment of tularemia with ciprofloxacin
162. Probe aims at sale of deadly bacteria
163. Antibody response in Crimean Congo hemorrhagic fever
164. Peripheral actions of the botulinum toxins
165. A large Q fever outbreak in the West Midlands: Clinical aspects
166. The chest X-ray in Q fever: A report of 69 cases from the 1989 West Midlands outbreak
167. Recognition and optimum treatment of brucellosis
168. Military significance of Q fever: A review
169. Toxicity of staphylococcal enterotoxins potentiated by lipopolysaccharide
170. Development of sensitive colorimetric capture elisas for Clostridium botulinum neurotoxin serotypes A and B
171. Primary pneumonic plague in Mukden, 1946, and report of 39 cases with 3 recoveries
172. Studies of Q fever in man
173. Historical trends related to bioterrorism: An empirical analysis
174. Proceedings of the International Workshop on Anthrax
175. Development of engineered vaccines effective against structurally related bacterial superantigens
176. Staphylococcal enterotoxin B and related pyrogenic toxins
177. A nosocomial outbreak of Crimean Congo hemorrhagic fever at Tygerberg Hospital
178. Validation of an enzyme immunoassay for serodiagnosis of acute Q fever
179. Suspicious package prompts 8-hour vigil at B'nai B'rith
180. An airborne outbreak of smallpox in a German hospital and its significance with respect to other recent outbreaks in Europe
181. Lesions of acute inhaled lethal ricin intoxication in Rhesus monkeys
182. Epitopes involved in anti-body-mediated protection from Ebola virus
183. Ebola hemorrhagic fever in Sudan, 1976
184. Ebola hemorrhagic fever in Zaire, 1976
185. Rapid detection of Brucella melitensis from blood cultures by a commercial system
186. Serologic diagnosis of human brucellosis: Analysis of 214 cases by agglutination tests and review of the literature
187. An overview of human brucellosis
188. Human monkeypox